Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, includi...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

YouOnlyLiveTwice Apr. 23 at 4:19 PM

$CRL All med device are sells …

0 · Reply

zerodayrounder Apr. 23 at 1:58 PM

$CRL this thing is cooked wow. AI eating its lunch?

0 · Reply

IN0V8 Apr. 15 at 4:04 PM

$CRL Buy Barclays raises target price to $210 from $200

0 · Reply

zerodayrounder Apr. 6 at 9:22 PM

$CRL why did this get smoked today? Trump MFN for drugs not good for these guys?

0 · Reply

koditrump Mar. 16 at 9:45 PM

$CNC $CRL

0 · Reply

koditrump Mar. 16 at 9:43 PM

$CRL $UAMY $TSLA $LYFT

0 · Reply

YouOnlyLiveTwice Mar. 10 at 2:44 PM

$CRL Time to short all medical device companies ….

0 · Reply

Estimize Mar. 9 at 1:06 PM

Wall St is expecting 1.94 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

smartkarma Feb. 28 at 9:02 PM

$CRL | Charles River Laboratories and China Expansion: Turning Regulatory Localization Into a Growth Advantage! "Charles River Laboratories' fourth-quarter and full-year 2025 financial results reflect a range of dynamics that present both positive and..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/charles-river-laboratories-and-china-expansion-turning-regulatory-localization-into-a-growth-advantage

0 · Reply

Estimize Feb. 23 at 3:00 PM

Wall St is expecting 1.93 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

Charles River Associates (CRA) to Host First-Quarter Fiscal 2026 Financial Results Conference Call on May 7

Apr 21, 2026, 8:00 AM EDT - 4 days ago

Charles River Highlights Effectiveness of VCGs in Toxicology

Apr 16, 2026, 8:00 AM EDT - 9 days ago

Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call

Apr 13, 2026, 11:41 AM EDT - 12 days ago

Earnings Season Is Here. Microsoft and 7 More Companies That Usually Deliver.

MSFT ADBE APH BSX INTU NVDA WDAY

Apr 9, 2026, 4:30 PM EDT - 15 days ago

Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association

Apr 6, 2026, 8:55 AM EDT - 19 days ago

NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX

Mar 2, 2026, 8:00 AM EST - 7 weeks ago

Charles River Laboratories to Present at TD Cowen and Barclays Conferences

Feb 25, 2026, 8:00 AM EST - 2 months ago

Charles River raises annual profit view as it sells underperforming assets

Feb 25, 2026, 7:00 AM EST - 2 months ago

Charles River Laboratories Provides Update on Planned Divestitures

Feb 18, 2026, 7:54 AM EST - 2 months ago

Charles River forecasts upbeat 2026 profit on improved demand for drug development services

Feb 18, 2026, 7:01 AM EST - 2 months ago

Charles River Laboratories Announces Executive Appointments

Feb 18, 2026, 7:00 AM EST - 2 months ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

Feb 12, 2026, 11:54 AM EST - 2 months ago

Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 21, 2026, 4:30 PM EST - 3 months ago

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

Jan 21, 2026, 8:00 AM EST - 3 months ago

Charles River Enters Manufacturing Collaboration with Gazi University

Jan 20, 2026, 3:39 PM EST - 3 months ago

Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL

Jan 12, 2026, 5:19 PM EST - 3 months ago

Charles River to buy Cambodia-based monkey supplier for $510 million

Jan 12, 2026, 4:30 PM EST - 3 months ago

Charles River Laboratories Provides Business Updates

Jan 8, 2026, 8:00 AM EST - 3 months ago

Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan

Dec 11, 2025, 8:00 AM EST - 4 months ago

Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort

Dec 4, 2025, 8:30 AM EST - 5 months ago

T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform

Dec 1, 2025, 3:42 PM EST - 5 months ago

HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 1, 2025, 8:00 AM EST - 5 months ago

Charles River Laboratories to Present at Evercore Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 5 months ago

SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers

Nov 17, 2025, 8:00 AM EST - 5 months ago

Charles River Laboratories to Present at Jefferies Global Healthcare Conference

Nov 5, 2025, 1:38 PM EST - 6 months ago

Charles River Beat Expectations But Why Is The Stock Falling?

Nov 5, 2025, 7:34 AM EST - 6 months ago

Charles River raises annual profit forecast on stabilizing biotech demand

Nov 5, 2025, 7:01 AM EST - 6 months ago

Charles River Laboratories Provides Update on Strategic Review

Nov 5, 2025, 7:00 AM EST - 6 months ago

Charles River Laboratories Announces Third-Quarter 2025 Results

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development

Oct 20, 2025, 8:00 AM EDT - 6 months ago

Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities

Oct 15, 2025, 8:00 AM EDT - 6 months ago

Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption

Oct 14, 2025, 8:00 AM EDT - 6 months ago

Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call

Oct 8, 2025, 8:00 AM EDT - 7 months ago

Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing

Oct 7, 2025, 7:22 AM EDT - 7 months ago

Why Charles River Stock May Struggle In Its Final Phase

Sep 16, 2025, 7:05 AM EDT - 7 months ago

Charles River Laboratories Announces Chief Financial Officer Transition

Sep 11, 2025, 8:00 AM EDT - 8 months ago

Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Sep 3, 2025, 8:00 AM EDT - 8 months ago

Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences

Aug 26, 2025, 8:00 AM EDT - 8 months ago

Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing

Aug 6, 2025, 12:50 PM EDT - 9 months ago

Charles River Sees Limited Impact From NIH Cuts, Tariffs, Drug Pricing

Aug 6, 2025, 7:55 AM EDT - 9 months ago

Charles River raises profit forecast on growing demand for drug development services

Aug 6, 2025, 7:00 AM EDT - 9 months ago

Charles River Laboratories Announces Second-Quarter 2025 Results

Jul 22, 2025, 8:00 AM EDT - 9 months ago

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Charles River Laboratories to Present at William Blair and Jefferies Conferences

May 28, 2025, 8:00 AM EDT - 11 months ago

Charles River and CHDI Foundation Extend Multi-Decade Collaboration on Huntington's Disease Research

May 13, 2025, 8:00 AM EDT - 1 year ago

Charles River Laboratories to Present at Bank of America Health Care Conference

May 10, 2025, 8:49 AM EDT - 1 year ago

Activist Elliott reaches key agreement with Charles River. Here are three ways to create value

YouOnlyLiveTwice Apr. 23 at 4:19 PM

$CRL All med device are sells …

0 · Reply

zerodayrounder Apr. 23 at 1:58 PM

$CRL this thing is cooked wow. AI eating its lunch?

0 · Reply

IN0V8 Apr. 15 at 4:04 PM

$CRL Buy Barclays raises target price to $210 from $200

0 · Reply

zerodayrounder Apr. 6 at 9:22 PM

$CRL why did this get smoked today? Trump MFN for drugs not good for these guys?

0 · Reply

koditrump Mar. 16 at 9:45 PM

$CNC $CRL

0 · Reply

koditrump Mar. 16 at 9:43 PM

$CRL $UAMY $TSLA $LYFT

0 · Reply

YouOnlyLiveTwice Mar. 10 at 2:44 PM

$CRL Time to short all medical device companies ….

0 · Reply

Estimize Mar. 9 at 1:06 PM

Wall St is expecting 1.94 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

smartkarma Feb. 28 at 9:02 PM

0 · Reply

Estimize Feb. 23 at 3:00 PM

Wall St is expecting 1.93 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

SuperGreenToday Feb. 23 at 10:04 AM

$CRL Share Price: $169.00 Contract Selected: Jul 17, 2026 $160 Calls Buy Zone: $18.79 – $23.21 Target Zone: $33.31 – $40.71 Potential Upside: 67% ROI Time to Expiration: 143 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Fletcher_13 Feb. 20 at 6:40 PM

$CRL 545k vol, staying flat until it commits toward 200.46 or rolls over

0 · Reply

RunnerSignals Feb. 20 at 11:31 AM

oversold bounce radar https://stocksrunner.com/news/2026-02-20-oversold-stocks-to-watch-today $CRL $ULS $ETSY $SMWB $PINS starting to wake up off the lows. setups getting interesting

0 · Reply

koditrump Feb. 18 at 7:19 PM

$CRL

0 · Reply

d_risk Feb. 18 at 3:53 PM

$CRL - Charles River Laboratories International Inc - 10K - Updated Risk Factors CRL flags new risks from deploying AI, a disruptive board-led strategic review (with possible deals, divestitures, and volatility), intensifying trade protectionism and tariffs, a major goodwill and intangible write-down in Biologics/Cell & Gene units, and regulatory moves to phase out animal testing that could pressure its core model. #BiotechIndustry #AIRisks #StrategicReview #TradeProtectionism #RegulatoryChanges 🟢 Added 🟠 Removed https://d-risk.ai/CRL/10-K/2026-02-18

0 · Reply

ZacksResearch Feb. 18 at 3:07 PM

$CRL beats Q4 estimates but shares dip — what gives? 🤔 📉 Adjusted EPS of $2.39 beats by 2.51%, yet shares fell 0.8% pre-market 📊 Revenues also topped estimates, despite a slight organic decline in revenues Understand the full picture here 👉 https://www.zacks.com/stock/news/2871047/crl-stock-down-despite-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2871047-body-34009&ADID=SYND_STOCKTWITS_TWEET_2_2871047_BODY_34009

0 · Reply

ZacksResearch Feb. 18 at 1:11 PM

$CRL beats on earnings and revenue… yet the stock drops? 🤔 Q4 delivered an earnings and revenue beat, and margins actually rose — but shares are still under pressure. When a company posts solid numbers and the market sells it anyway, there’s usually more beneath the surface. Is this a short-term shakeout or a warning sign? Get the full breakdown here 👉 https://www.zacks.com/stock/news/2871047/crl-stock-down-despite-q4-earnings-revenue-beat-margins-rise?cid=sm-stocktwits-2-2871047-teaser-33919&ADID=SYND_STOCKTWITS_TWEET_2_2871047_TEASER_33919

0 · Reply

StocktwitsEarnings Feb. 18 at 12:21 PM

$CRL Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$5.62 down -33.18% YoY • Reported revenue of $994.23M down -0.83% YoY • Charles River Laboratories expects 2026 organic revenue growth to be (1.0)% to At Least Flat, and non-GAAP EPS is estimated to be $10.70-$11.20, an increase of approximately 4% to 9%.

0 · Reply

Estimize Feb. 18 at 11:00 AM

$CRL reported - EPS and - revenue for Q4. http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_content=CRL&utm_medium=act

0 · Reply

ZacksResearch Feb. 13 at 3:53 PM

$CRL Q4 Earnings: Will the past success repeat? 🤔 Despite a streak of earnings surprises, CRL's Q4 forecasts suggest a 1.7% revenue dip and a 12.4% EPS decline YoY. With a Zacks Rank #3 and negative Earnings ESP, an earnings beat seems unlikely this time. Full analysis here 👉 https://www.zacks.com/stock/news/2868912/heres-how-charles-river-stock-is-placed-ahead-of-q4-earnings?cid=sm-stocktwits-2-2868912-body-33529&ADID=SYND_STOCKTWITS_TWEET_2_2868912_BODY_33529

0 · Reply

ZacksResearch Feb. 13 at 2:53 PM

$CRL into Q4 — strength under the surface or cracks forming? 👀 The company heads into earnings backed by collaborations and solid momentum in RMS and Manufacturing, but DSA headwinds are weighing on revenue expectations. Mixed signals going into the print. Do the positives outweigh the pressure this quarter? Full setup ahead of Q4 👉 https://www.zacks.com/stock/news/2868912/heres-how-charles-river-stock-is-placed-ahead-of-q4-earnings?cid=sm-stocktwits-2-2868912-teaser-33525&ADID=SYND_STOCKTWITS_TWEET_2_2868912_TEASER_33525

0 · Reply

Sam201 Feb. 12 at 4:30 PM

$CRL Nice!!😊

0 · Reply

Market Cap	8.28B
Revenue (ttm)	4.02B
Net Income (ttm)	-144.34M
EPS (ttm)	N/A
PE Ratio	17.98
Forward PE	16.85
Profit Margin	-3.59%
Debt to Equity Ratio	0.67

Volume	716,300
Avg Vol	1,039,798
Day's Range	N/A - N/A
Shares Out	49.34M
Stochastic %K	17%
Beta	1.61
Analysts	Strong Sell
Price Target	$204.00